Stockreport

Catalyst Biosciences Completes Phase 2b Trial of Subcutaneous Factor IX Dalcinonacog Alfa (DalcA)

Crescent Biopharma, Inc.  (CBIO) 
Last crescent biopharma, inc. earnings: 11/7 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: catalystbiosciences.com/investors
PDF SOUTH SAN FRANCISCO, Calif., April 21, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), a biopharmaceutical company developing novel subcutaneous (S [Read more]